ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
22.461,52
-0,89%
S&P 500
5.580,94
-1,97%
Dow Jones
41.583,90
-1,69%
Euro vs US Dollar
1,08845
-0,01%
Bitcoin
82.572,34
-2,10%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Puma Biotechnology Inc (PBYI)

  7. Puma Biotechnology Inc (PBYI) News

PBYI

Puma Biotechnology (PBYI)

Puma Biotechnology Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:PBYI
DatumZeitQuelleÜberschriftSymbolFirma
26/03/202514h00Business WirePuma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025NASDAQ:PBYIPuma Biotechnology Inc
27/02/202522h41Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PBYIPuma Biotechnology Inc
27/02/202522h22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBYIPuma Biotechnology Inc
27/02/202522h05Business WirePuma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:PBYIPuma Biotechnology Inc
26/02/202522h15Business WirePuma Biotechnology to Present at TD Cowen’s 45th Annual Health Care ConferenceNASDAQ:PBYIPuma Biotechnology Inc
14/02/202518h14Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:PBYIPuma Biotechnology Inc
14/02/202517h11Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:PBYIPuma Biotechnology Inc
14/02/202514h34Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:PBYIPuma Biotechnology Inc
13/02/202522h15Business WirePuma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:PBYIPuma Biotechnology Inc
12/02/202500h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PBYIPuma Biotechnology Inc
05/02/202523h05Business WirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PBYIPuma Biotechnology Inc
04/01/202501h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PBYIPuma Biotechnology Inc
04/01/202501h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PBYIPuma Biotechnology Inc
04/01/202501h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PBYIPuma Biotechnology Inc
03/01/202523h15Business WirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PBYIPuma Biotechnology Inc
03/01/202502h37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PBYIPuma Biotechnology Inc
03/01/202502h34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PBYIPuma Biotechnology Inc
03/01/202502h33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PBYIPuma Biotechnology Inc
23/12/202415h01Business WirePuma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 MutationNASDAQ:PBYIPuma Biotechnology Inc
04/12/202423h15Business WirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PBYIPuma Biotechnology Inc
20/11/202414h57Business WirePuma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast CancerNASDAQ:PBYIPuma Biotechnology Inc
14/11/202418h12Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:PBYIPuma Biotechnology Inc
08/11/202423h31Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:PBYIPuma Biotechnology Inc
07/11/202422h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBYIPuma Biotechnology Inc
07/11/202422h05Business WirePuma Biotechnology Reports Third Quarter 2024 Financial ResultsNASDAQ:PBYIPuma Biotechnology Inc
05/11/202423h15Business WirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PBYIPuma Biotechnology Inc
24/10/202422h07Business WirePuma Biotechnology to Host Conference Call to Discuss Third Quarter Financial ResultsNASDAQ:PBYIPuma Biotechnology Inc
22/10/202421h24Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:PBYIPuma Biotechnology Inc
16/09/202415h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBYIPuma Biotechnology Inc
03/09/202422h15Business WirePuma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:PBYIPuma Biotechnology Inc
 Showing the most relevant articles for your search:NASDAQ:PBYI

Kürzlich von Ihnen besucht

LSE
47FL
Barclays.25
TG
ACWN
Wallpaper NA AS Creation
LSE
0MUF
Cenit
TG
17W
WiseTech Global
LSE
0K9U
Hellenic Petroleum
LSE
CW70
Roy.bk.can.23
LSE
0HC3
Alaska Air
LSE
TK23
Barclays 26
LSE
MCLS
Mccoll's Retail
TG
BPM
Banco BPM
BIT
AIGC
ETFS All Commodities
LSE
78UM
Barclays.27
NASDAQ
FCNJX
Bmg Gold Bullionfund Cla...
TG
0VVB
Paramount Global
LSE
16IM
Bhp Fin. 4.30%
TG
LGX1
China Resources Gas
Delayed Upgrade Clock
ADVFN Logo
Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten